TY - JOUR
T1 - Targeting tuberculosis and malaria through inhibition of enoyl reductase. Compound activity and structural data
AU - Kuo, Mack R.
AU - Morbidoni, Hector R.
AU - Alland, David
AU - Sneddon, Scott F.
AU - Gourlie, Brian B.
AU - Staveski, Mark M.
AU - Leonard, Marina
AU - Gregory, Jill S.
AU - Janjigian, Andrew D.
AU - Yee, Christopher
AU - Musser, James M.
AU - Kreiswirth, Barry
AU - Iwamoto, Hiroyuki
AU - Perozzo, Remo
AU - Jacobs, William R.
AU - Sacchettini, James C.
AU - Fidock, David A.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2003/6/6
Y1 - 2003/6/6
N2 - Tuberculosis and malaria together result in an estimated 5 million deaths annually. The spread of multidrug resistance in the most pathogenic causative agents, Mycobacterium tuberculosis and Plasmodium falciparum, underscores the need to identify active compounds with novel inhibitory properties. Although genetically unrelated, both organisms use a type II fatty-acid synthase system. Enoyl acyl carrier protein reductase (ENR), a key type II enzyme, has been repeatedly validated as an effective antimicrobial target. Using high throughput inhibitor screens with a combinatorial library, we have identified two novel classes of compounds with activity against the M. tuberculosis and P. falciparum enzyme (referred to as InhA and PfENR, respectively). The crystal structure of InhA complexed with NAD+ and one of the inhibitors was determined to elucidate the mode of binding. Structural analysis of InhA with the broad spectrum antimicrobial triclosan revealed a unique stoichiometry where the enzyme contained either a single triclosan molecule, in a configuration typical of other bacterial ENR:triclosan structures, or harbored two triclosan molecules bound to the active site. Significantly, these compounds do not require activation and are effective against wild-type and drug-resistant strains of M. tuberculosis and P. falciparum. Moreover, they provide broader chemical diversity and elucidate key elements of inhibitor binding to InhA for subsequent chemical optimization.
AB - Tuberculosis and malaria together result in an estimated 5 million deaths annually. The spread of multidrug resistance in the most pathogenic causative agents, Mycobacterium tuberculosis and Plasmodium falciparum, underscores the need to identify active compounds with novel inhibitory properties. Although genetically unrelated, both organisms use a type II fatty-acid synthase system. Enoyl acyl carrier protein reductase (ENR), a key type II enzyme, has been repeatedly validated as an effective antimicrobial target. Using high throughput inhibitor screens with a combinatorial library, we have identified two novel classes of compounds with activity against the M. tuberculosis and P. falciparum enzyme (referred to as InhA and PfENR, respectively). The crystal structure of InhA complexed with NAD+ and one of the inhibitors was determined to elucidate the mode of binding. Structural analysis of InhA with the broad spectrum antimicrobial triclosan revealed a unique stoichiometry where the enzyme contained either a single triclosan molecule, in a configuration typical of other bacterial ENR:triclosan structures, or harbored two triclosan molecules bound to the active site. Significantly, these compounds do not require activation and are effective against wild-type and drug-resistant strains of M. tuberculosis and P. falciparum. Moreover, they provide broader chemical diversity and elucidate key elements of inhibitor binding to InhA for subsequent chemical optimization.
UR - http://www.scopus.com/inward/record.url?scp=0038757566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038757566&partnerID=8YFLogxK
U2 - 10.1074/jbc.M211968200
DO - 10.1074/jbc.M211968200
M3 - Article
C2 - 12606558
AN - SCOPUS:0038757566
SN - 0021-9258
VL - 278
SP - 20851
EP - 20859
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 23
ER -